U.S. Markets closed
  • S&P Futures

    4,534.50
    +10.25 (+0.23%)
     
  • Dow Futures

    34,977.00
    +67.00 (+0.19%)
     
  • Nasdaq Futures

    15,084.75
    +51.25 (+0.34%)
     
  • Russell 2000 Futures

    2,061.90
    +2.70 (+0.13%)
     
  • Crude Oil

    86.55
    -0.41 (-0.47%)
     
  • Gold

    1,841.30
    -1.90 (-0.10%)
     
  • Silver

    24.25
    +0.01 (+0.06%)
     
  • EUR/USD

    1.1357
    +0.0010 (+0.0909%)
     
  • 10-Yr Bond

    1.8270
    -0.0380 (-2.04%)
     
  • Vix

    23.85
    +1.06 (+4.65%)
     
  • GBP/USD

    1.3627
    +0.0015 (+0.1131%)
     
  • USD/JPY

    114.3470
    -0.0060 (-0.0052%)
     
  • BTC-USD

    41,969.79
    -298.35 (-0.71%)
     
  • CMC Crypto 200

    994.60
    -0.15 (-0.02%)
     
  • FTSE 100

    7,589.66
    +26.11 (+0.35%)
     
  • Nikkei 225

    27,594.29
    +127.06 (+0.46%)
     

Kala Pharmaceuticals Announces Time Change for Third Quarter 2021 Financial Results Conference Call

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has changed the time of its previously scheduled financial results conference call and live audio webcast. The Company will now report its third quarter 2021 financial results and provide a business update on Monday, November 15th at 10:30 am. ET.

The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 7298039. To access a live webcast and subsequent archived recording of the call, please visit “Events” in the “Investor” section on the Kala website at http://kalarx.com/.

About Kala Pharmaceuticals, Inc.

Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.

Investor Contacts:
Jill Steier
jill.steier@kalarx.com
781-996-5252

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200